Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 44

1.

The β-NAD+ salvage pathway and PKC-mediated signaling influence localized PARP-1 activity and CTCF Poly(ADP)ribosylation.

Henderson DJP, Miranda JL, Emerson BM.

Oncotarget. 2017 Aug 3;8(39):64698-64713. doi: 10.18632/oncotarget.19841. eCollection 2017 Sep 12.

2.

Genome-wide targeting of the epigenetic regulatory protein CTCF to gene promoters by the transcription factor TFII-I.

Peña-Hernández R, Marques M, Hilmi K, Zhao T, Saad A, Alaoui-Jamali MA, del Rincon SV, Ashworth T, Roy AL, Emerson BM, Witcher M.

Proc Natl Acad Sci U S A. 2015 Feb 17;112(7):E677-86. doi: 10.1073/pnas.1416674112. Epub 2015 Feb 2.

3.

Single-cell analyses of transcriptional heterogeneity during drug tolerance transition in cancer cells by RNA sequencing.

Lee MC, Lopez-Diaz FJ, Khan SY, Tariq MA, Dayn Y, Vaske CJ, Radenbaugh AJ, Kim HJ, Emerson BM, Pourmand N.

Proc Natl Acad Sci U S A. 2014 Nov 4;111(44):E4726-35. doi: 10.1073/pnas.1404656111. Epub 2014 Oct 22.

4.
5.

Coordinate transcriptional and translational repression of p53 by TGF-β1 impairs the stress response.

López-Díaz FJ, Gascard P, Balakrishnan SK, Zhao J, Del Rincon SV, Spruck C, Tlsty TD, Emerson BM.

Mol Cell. 2013 May 23;50(4):552-64. doi: 10.1016/j.molcel.2013.04.029.

6.

Functional and molecular characterization of the role of CTCF in human embryonic stem cell biology.

Balakrishnan SK, Witcher M, Berggren TW, Emerson BM.

PLoS One. 2012;7(8):e42424. doi: 10.1371/journal.pone.0042424. Epub 2012 Aug 3.

7.

An analogy between the evolution of drug resistance in bacterial communities and malignant tissues.

Lambert G, Estévez-Salmeron L, Oh S, Liao D, Emerson BM, Tlsty TD, Austin RH.

Nat Rev Cancer. 2011 May;11(5):375-82. doi: 10.1038/nrc3039. Review.

8.

Identification of kinase inhibitors that target transcription initiation by RNA polymerase II.

Morachis JM, Huang R, Emerson BM.

Oncotarget. 2011 Jan-Feb;2(1-2):18-28.

9.

Regulation of the p53 transcriptional response by structurally diverse core promoters.

Morachis JM, Murawsky CM, Emerson BM.

Genes Dev. 2010 Jan 15;24(2):135-47. doi: 10.1101/gad.1856710. Epub 2009 Dec 29.

10.

Epigenetic silencing of the p16(INK4a) tumor suppressor is associated with loss of CTCF binding and a chromatin boundary.

Witcher M, Emerson BM.

Mol Cell. 2009 May 15;34(3):271-84. doi: 10.1016/j.molcel.2009.04.001.

11.

BRD7, a novel PBAF-specific SWI/SNF subunit, is required for target gene activation and repression in embryonic stem cells.

Kaeser MD, Aslanian A, Dong MQ, Yates JR 3rd, Emerson BM.

J Biol Chem. 2008 Nov 21;283(47):32254-63. doi: 10.1074/jbc.M806061200. Epub 2008 Sep 22.

12.

Remodeling plans for cellular specialization: unique styles for every room.

Kaeser MD, Emerson BM.

Curr Opin Genet Dev. 2006 Oct;16(5):508-12. Epub 2006 Aug 14. Review.

PMID:
16905306
13.

Gene-specific requirement for P-TEFb activity and RNA polymerase II phosphorylation within the p53 transcriptional program.

Gomes NP, Bjerke G, Llorente B, Szostek SA, Emerson BM, Espinosa JM.

Genes Dev. 2006 Mar 1;20(5):601-12.

14.
15.

A methylation-mediator complex in hormone signaling.

Xu W, Cho H, Kadam S, Banayo EM, Anderson S, Yates JR 3rd, Emerson BM, Evans RM.

Genes Dev. 2004 Jan 15;18(2):144-56. Epub 2004 Jan 16.

16.
17.
18.

Mechanisms of chromatin assembly and transcription.

Kadam S, Emerson BM.

Curr Opin Cell Biol. 2002 Jun;14(3):262-8. Review.

PMID:
12067647
19.

Specificity of gene regulation.

Emerson BM.

Cell. 2002 May 3;109(3):267-70. Review.

20.

A transcriptional switch mediated by cofactor methylation.

Xu W, Chen H, Du K, Asahara H, Tini M, Emerson BM, Montminy M, Evans RM.

Science. 2001 Dec 21;294(5551):2507-11. Epub 2001 Nov 8.

Supplemental Content

Loading ...
Support Center